Clinical Trial Update: Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study of UniCAR02-T-CD123 in CD123-positive hematologic malignancies has been terminated, with Acute Myeloid Leukemia included among the conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• UniCAR02-T-CD123

Snippet

Sponsor: AvenCell Europe GmbH | Conditions: Acute Myeloid Leukemia (AML) | Phase 1 | Status: TERMINATED